SEPTIN7P11

Across TCGA pan-cancer cohorts, SEPTIN7P11 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SEPTIN7P11 data layer compared with 13 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SEPTIN7P11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SEPTIN7P11 expression acts as an unfavorable survival marker.

LIHC, ESCA, and HNSC are the cancer types where SEPTIN7P11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.198	0.777	.006	18	view →
ESCA	OS	Median	II,III,IV	0.206	0.686	.004	12	view →
HNSC	OS	Median	All	0.151	0.685	.007	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SEPTIN7P11–LIHC (OS)

Open the LIHC breakdown →